Financial Performance - The net loss from continuing operations for the year ended December 31, 2025, was $3,595,000, a decrease of $724,000, or 17%, compared to the previous year [286]. - Total net loss for the year ended December 31, 2025, was $4,156,000, a decrease of $1,191,000, or 22%, compared to $5,347,000 for the year ended December 31, 2024 [289]. - The accumulated deficit as of December 31, 2025, was $38,557,000, indicating ongoing financial challenges and reliance on external financing [307]. - The company expects to incur losses for the foreseeable future and has substantial doubt about its ability to continue as a going concern [309]. Expenses - Research and development expenses for the year ended December 31, 2025, were $179,000, compared to $0 for the year ended December 31, 2024, reflecting increased activities following the acquisition of MitoCareX [280]. - General and administrative expenses increased by $1,826,000, or 56%, to $5,109,000 for the year ended December 31, 2025, primarily due to higher share-based compensation and professional services [281]. - Financing expenses, net for the year ended December 31, 2025, were $1,545,000, an increase of $1,293,000, or 513%, compared to the previous year [284]. Cash Flow - As of December 31, 2025, the company had cash and cash equivalents of $3,832,000, an increase from $1,923,000 as of December 31, 2024 [295]. - The company reported a net cash used in operating activities of $3,808,000 for 2025, compared to $3,419,000 for 2024, reflecting an increase in cash outflows [296]. - Net cash used in investing activities rose to $3,233,000 in 2025 from $1,889,000 in 2024, primarily due to investments in renewable energy projects and the acquisition of MitoCareX [298]. - The company generated net cash provided by financing activities of $8,856,000 in 2025, up from $3,047,000 in 2024, largely due to proceeds from standby equity purchase agreements [299]. Shareholder Information - The weighted average number of shares of common stock outstanding (basic) increased to 1,132,707 for the year ended December 31, 2025, compared to 187,215 for the previous year [279]. Strategic Agreements and Operations - The company entered into a Services Agreement with Voice Assist, which includes deferred cash consideration of up to $1,000,000 and ongoing royalty consideration based on gross profits from new projects [268]. - The company completed the sale of its NTWO OFF Ltd. operations in April 2025, impacting the financial results for the year [263]. - The company classified its Save Foods operations as held for sale and discontinued operations during 2025, affecting the overall financial performance [263]. Future Financing - Existing capital resources are projected to support operations through the first quarter of 2027, but additional capital may be needed for growth initiatives [308]. - The company entered into a purchase agreement with an investor for up to $20 million in common stock over 36 months, with shares priced at 94% of the lowest VWAP [301]. - A facility agreement was established with L.I.A. Pure Capital for a credit facility of up to EUR 6,000,000, including a five-year warrant for shares [304]. - The company raised approximately $1,500,000 in a private placement, issuing 6,250,000 units at a price of $0.24 per unit [305].
Save Foods(SVFD) - 2025 Q4 - Annual Report